Compound ID | 491
REP 6021
Class: DNA synthesis inhibitor (pyrimidinone (thioxo-thiazolidin-4-one series))
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | DNA synthesis inhibitor by targetting DNA polymerase III |
| Institute where first reported: | GSK, USA; Replidyne, Inc., (Cardiovascular Systems, Inc, USA) |
| Year first mentioned: | 2004 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| Reason Dropped: | Replidyne suspended development of this compound due to need of additional investment (S1) |
| External links: | |
| Citation: | http://adis.springer.com/drugs/800019084 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.